金唯智母公司Brooks Automation计划分拆为两家独立的上市公司
美国马萨诸塞州，2021年5月10日，金唯智母公司Brooks Automation宣布计划拆分为两家独立的上市企业，创办业务聚焦且高速增长的生命科学企业与自动化企业。预计在2021年12月底以前完成所有程序。
该交易旨在以节税的方式向Brooks的股东按比例分配股份，拆分后将成立：
- 222一家专注的生命科学公司，拥有市场领先的基于样本的解决方案和基因组学服务。公司将在拆分完成前重新命名，以反映其战略重点。截至2021年3月31日的十二个月中，该业务创造了4.49亿美元的营收。222
- 222一家高度创新的自动化技术公司，在半导体制造解决方案方面具有丰富的经验，并拥有可扩展到多个行业的自动化应用领域的市场潜力。拆分将保留Brooks Automation的名称，这是对其多年来建立的业务的证明。截至2021年3月31日的十二个月，该业务的营收为5.53亿美元。222
“这对Brooks来说是激动人心的一天，代表了我们公司长期战略的一个重要里程碑。在过去的十年中，我们已经成功地在生命科学和自动化领域建立了两个强大的业务体系，”Brooks总裁兼首席执行官Steve Schwartz对此评价说。
Brooks董事会主席Dave Jarzynka说：“公司拆分是董事会和管理团队进行全面战略审查的结果。创建两个独立的公司，每个公司都有各自的重点和成熟的业务模式，旨在推动这两个业务的持续发展并为股东创造价值。”
Brooks现任首席执行官Steve Schwartz将领导独立的生命科学公司。现任Brooks CFO Lindon Robertson将担任CFO。该公司将包括Brooks的生命科学业务。
半导体解决方案事业部现任总裁DaveJarzynka将被任命为新的Brooks Automation的首席执行官。Brooks现任公司财务总监兼首席会计官Dave Pietrantoni将被任命为首席财务官。该公司将由Brooks的半导体解决方案业务组成，其中包括2021年4月29日收购的协作机器人和多市场自动化业务。
拆分战略的决策依据
生命科学和半导体业务在不同的行业市场中运营，具有独特的商机和投资要求。Brooks董事会和管理层认为，拆分将为独立公司带来实质性收益，其中包括：
- 增强战略和运营聚焦
- 简化组织结构并提高灵活性
- 独特而清晰的财务状况，具有令人信服的投资案例
- 一致的绩效激励机制
- 优质的资产负债表支持有机和无机投资
拆分细节
这项交易计划将以节税的方式按比例向Brooks股东分配股票。Brooks的目标是在2021日历年末完成拆分。拆分的完成取决于惯例市场、法规和其他条件。拆分的更多细节将在将来向美国证券交易委员会提交的文件中披露。此次拆分不需要股东投票。不能保证拆分或完成的形式和时间。
Evercore担任财务顾问，Paul，Weiss，Rifkind，Wharton＆GarrisonLLP担任Brooks法律顾问。
关于BROOKS AUTOMATION
BROOKS AUTOMATION是一家提供自动化、真空和仪器仪表解决方案的世界顶级供应商，其服务对象为包括半导体制造、工艺设备制造和生命科学领域的公共市场。该公司的技术、工程能力和全球服务能力帮助客户快速进入市场并确保其正常运营灵活应变，这也是在他们的关键任务控制环境中的重要价值。自1978年以来，该公司一直是全球半导体制造市场的主要合作伙伴，且通过产品开发计划和战略业务收购，其已扩大了公司的业务范围以满足客户在相邻的半导体和生命科学技术市场的需求。该公司总部设在马萨诸塞州的切姆斯福德，在北美、欧洲和亚洲有全业务运营。
有关更多信息，请访问www.brooks.com。
根据1934年《证券交易法》第21E条的“安全港声明”
本新闻稿中的某些陈述是根据1934年《证券交易法》第21E条作出的前瞻性陈述。这些陈述既不是承诺，也不是保证，而是涉及已知和未知的风险和不确定性，可能导致Brooks的财务和业务成果与我们的期望存在重大差异。它们基于制造时管理层已知的事实。这些前瞻性陈述包括但不限于有关影响Brooks生命科学和半导体解决方案集团业务拆分的能力以及独立公司的预期业绩的陈述。可能导致结果与我们的预期不同的因素包括：COVID-19全球大流行对我们服务的市场的影响；全球政治和经济状况的不确定性以及其他因素和其他风险，包括我们在提交给美国证券交易委员会的文件中所描述的不确定因素，包括但不限于我们关于10-K表格的年度报告，关于8表格的最新报告 -K和我们在表格10-Q上的季度报告。
关于金唯智
GENEWIZ（金唯智）成立于1999年，总部位于美国新泽西州，是专注于基因组研究和基因技术应用的生物高科技公司。金唯智在全球范围内为科学研究人员提供高通量测序、基因编辑、Sanger测序、基因合成、引物合成、分子生物学服务及GLP标准规范服务。基于金唯智严谨的科学和卓越的服务，包括近30位诺贝尔奖获得者在内的众多科研工作者已成为金唯智的忠实客户，全球诸多知名跨国公司以及著名高等学府也把金唯智选为其战略合作伙伴和首选供应商。2018年，金唯智正式加入Brooks集团，成为纳斯达克上市公司的一部分。
英文原文：
BROOKSANNOUNCES INTENTION TO SEPARATE INTO TWO INDEPENDENT PUBLICLY TRADED COMPANIES
CHELMSFORD,Mass., May 10, 2021 / Brooks Automation, Inc. (“Brooks”)(Nasdaq: BRKS) today announced its intention to separate its business into twoindependent, and publicly-traded companies.
The transaction is intended to bestructured as a pro-rata distribution of shares to Brooks shareholders in atax-efficient manner and will establish:
- A pure-play life sciences company with market-leadingsample-based solutions and genomics services. The company will be renamedbefore the separation is completed to reflect its strategic focus.This businessgenerated revenue of $449 million in the twelvemonths ending March 31, 2021.
- A highly innovative automation technology company withsignificant expertise in semiconductor manufacturing solutions and meaningfulwhite space to expand into multi-market automation. The company will retain theBrooks Automation name, a testament to the legacy it has built over the years.This business generated revenue of $553 million for the lasttwelve months ending March 31, 2021.
“This is an exciting day for Brooks and represents a criticalmilestone in our long-term strategy for the company. Over the past decade, wehave successfully built two strong businesses in life sciences andautomation,” said Steve Schwartz,President and CEO of Brooks. “We are convinced the separation will betterposition each of them to extend their advantages in the markets theyserve.”
“Today’s announcement is the result of a thorough strategic reviewconducted by the Board and the management team,” said Joseph R. Martin, Chairman of the Board of Brooks.”The creation of two independent companies, each with a distinct focus anda proven business model, is intended to drive continued momentum in both businessesand deliver shareholder value.”
Current Brooks CEO, Steve Schwartz willlead the standalone life sciences company; current Brooks CFO, Lindon Robertson, will serve as CFO. The company will be comprised of Brooks’ LifeSciences business.
Following the separation, Dave Jarzynka, currentPresident of the Semiconductor Solutions Group business, will be named CEO ofthe new Brooks Automation; current Brooks Corporate Controller and PrincipalAccounting Officer, Dave Pietrantoni, will be namedCFO. The company will be comprised of Brooks’ Semiconductor Solutionsbusiness, which includes the collaborative robotics and multi-market automationbusiness acquired on April 29, 2021.
Compelling Strategic Rationale for a Separation
The life sciences and semiconductorbusinesses operate in distinct markets, with unique business opportunities andinvestment requirements. The Brooks Board andmanagement believe the separation will result in material benefits to the standalone companies,including:
- Enhanced strategic and operational focus
- Simplified organizational structures and improved agility
- Distinct and clear financial profiles with compellinginvestment cases
- Aligned performance incentives
- Strong balance sheets to support organic and inorganicinvestments
Separation Details
The transaction is planned to be a prorata distribution of shares to Brooks shareholders in a tax-efficient manner.Brooks is targeting completion of the separation by the end of calendar year2021. Completion of the separation is subject to customary market, regulatory,and other conditions. Further details on the separation will be included infuture filings with the Securities and Exchange Commission. The separation willnot require a shareholder vote. There can be no assurance regarding the formand timing of the separation or its completion.
Evercore is serving as financial advisor, and Paul,Weiss, Rifkind, Wharton & Garrison LLP is serving as legal advisorto Brooks.
Conference Calland Investor Presentation Today
The Company will host a conference call and live webcast to discuss theannouncement today, in conjunction with the previously scheduled Q2 EarningsCall, at 4:30 p.m. Eastern Time. To participate in theconference call, please dial 800-913-8744 for domestic callers and+1-212-271-4615 for international callers.
Analysts, investors and members of the media can access the live webcastvia the Brooks website at https://brooks.investorroom.com/events. A replaywill be available beginning at 8:30 a.m. ET on May 11, 2021.
About Brooks Automation, Inc.
Brooks (Nasdaq: BRKS) is a leading provider of life science sample-basedsolutions and semiconductor manufacturing solutions worldwide. With over40 years as a partner to the semiconductor manufacturing industry, Brooks is aprovider of industry-leading precision vacuum robotics, integrated automationsystems and contamination control solutions to the world’s leadingsemiconductor chip makers and equipment manufacturers. The Company’s LifeSciences business provides a full suite of reliable cold-chain samplemanagement solutions and genomic services across areas such as drugdevelopment, clinical research and advanced cell therapies for the industry’stop pharmaceutical, biotech, academic and healthcare institutionsglobally. Brooks Life Sciences’ GENEWIZ division is a leading provider ofgene sequencing and gene synthesis services. Brooks isheadquartered in Chelmsford, MA, with operationsin North America, Europe andAsia. For more information, visit www.brooks.com.
“Safe Harbor Statement” underSection 21E of the Securities Exchange Act of 1934
Some statementsin this release are forward-looking statements made under Section 21E of theSecurities Exchange Act of 1934. These statements are neither promises norguarantees but involve risks and uncertainties, both known and unknown, thatcould cause Brooks’ financial and business results to differ materially fromour expectations. They are based on the facts known to management at the timethey are made. These forward-looking statements include but are not limited tostatements about the ability to affect the separation of Brooks’ Life Sciencesand Semiconductor Solutions Group businesses and the projected performance ofthe standalone companies. Factors that could cause results to differ from ourexpectations include the following: the impact of the COVID-19 globalpandemic on the markets we serve; uncertainties in global political andeconomic conditions, and other factors and other risks, including those that wehave described in our filings with the Securities and Exchange Commission,including but not limited to our Annual Report on Form 10-K, current reports onForm 8-K and our quarterly reports on Form 10-Q.
INVESTOR CONTACTS:
Sara Silverman
Director, Investor Relations
Brooks Automation
978.262.2635
sara.silverman@brooks.com
Sherry Dinsmore
Brooks Automation
978.262.4301
sherry.dinsmore@brooks.com
